Small-scale isolation of synaptic vesicles from mammalian brain by Ahmed, Saheeb et al.
IntroDuctIon
SVs are essential organelles found in the presynaptic terminal 
that act as a store of neurotransmitters. After Ca2 +  influx into the 
presynaptic terminal during an action potential, SVs fuse with the 
plasma membrane (exocytosis), resulting in the release of neuro-
transmitters. After exocytosis, the SV membrane is recovered by 
endocytosis and used to reform vesicles, which are then refilled with 
neurotransmitters and used for subsequent rounds of exocytosis. 
Thus, understanding the composition of these vesicles and how 
this influences their trafficking within the presynaptic terminal is 
essential to understanding neurotransmitter release.
Protocols for isolating SVs from brain tissue were originally devel-
oped in the 1960s. Biochemical characterization of these early prepa-
rations was instrumental in proving that SVs are storage organelles for 
neurotransmitters, although many of the trafficking proteins known 
to be instrumental in membrane docking and fusion were also first 
identified in purified SVs1. In fact, interest in the biochemical char-
acterization of the SV continues unabated, as documented by several 
recent studies addressing the SV proteome2,3. Furthermore, numerous 
transgenic mouse lines, with defined changes in presynaptic protein 
expression, are now available (http://www.jax.org/), indicating that 
reliable protocols are needed to allow the high-yield and high-purity 
isolation of vesicles from small amounts of starting material. Here we 
describe the process for obtaining such a preparation.
Methods for isolating SVs
With an average diameter of 40–50 nm, SVs are among the small-
est trafficking organelles in mammalian cells. In addition, they are 
highly abundant in brain tissue, with ~5% of the total protein con-
tent of the mammalian central nervous system being contributed 
by SV proteins. It is these two remarkable properties that allow 
the application of standard subcellular fractionation techniques 
to SV purification. After the first description of a protocol for the 
isolation of vesicles from brain extracts4,5, a large number of pro-
cedures were developed (which are comprehensively reviewed by 
Whittaker6 and summarized in Fig. 1).
The conventional methods for isolation of SVs can be divided 
into two main groups. The first involves the intermediate isolation 
of isolated nerve terminals (synaptosomes), which are generated 
during gentle homogenization of brain tissue7. SVs are then released 
by hypotonic rupture of synaptosomes and are further purified by 
differential and density-gradient centrifugation. The advantage of 
this procedure is that synaptosomes are comparatively large parti-
cles that sediment at low g-forces, whereas smaller particles (such 
as ribosomes), membrane fragments or small vesicles from other 
sources all remain in the supernatant. After osmotic lysis, larger 
particles (including plasma membranes, mitochondria and myelin) 
are removed by differential centrifugation, leaving a supernatant 
highly enriched in SVs. The disadvantage of this procedure is that 
during initial homogenization many nerve terminals are damaged 
and release their SVs (at least partially) into the supernatant, result-
ing in a major loss of vesicles and thus low final yields.
The second group of protocols involves direct isolation of SVs 
from brain homogenates. Accordingly, homogenization conditions 
can be harsher, and protocols using shock-frozen brains have even 
been described8. These protocols usually allow for higher yields, but 
it is more difficult to remove contaminating membranes and par-
ticles, normally resulting in lower purity. To obtain higher purity, 
further loss occurs during additional purification that cancels out 
any initial improvements in the yield.
In both cases, further purification usually involves a combina-
tion of differential centrifugation and density-gradient centrifu-
gation. Differential centrifugation takes advantage of the fact that 
vesicles are among the smallest organelles known, with high-speed 
ultracentrifugation being required to pellet them. Therefore, SV- 
containing samples can be precentrifuged at relatively high g-forces, 
pelleting the larger membranes, leaving the SVs free in the superna-
tant. Density gradients are subsequently carried out as rate-zonal 
centrifugations, in which SVs migrate as a band that can be col-
lected after it has separated away from contaminants. Alternatively, 
it is possible to enrich SVs by isopycnic density-gradient centrifu-
gation; however, because of the small size of the vesicles, very long 
centrifugation times are required before density equilibrium is 
reached. Owing to the small and homogenous size of SVs, size-
exclusion chromatography is frequently used as a final purification 
step to further remove contaminating membranes and (if needed) 
any remaining cytosolic proteins.
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synaptic vesicles (sVs) are essential organelles that participate in the release of neurotransmitters from a neuron. Biochemical 
analysis of purified sVs was instrumental in the identification of proteins involved in exocytotic membrane fusion and 
neurotransmitter uptake. although numerous protocols have been published detailing the isolation of sVs from the brain, those 
that give the highest-purity vesicles often have low yields. Here we describe a protocol for the small-scale isolation of sVs from 
mouse and rat brain. the procedure relies on standard fractionation techniques, including differential centrifugation, rate-zonal 
centrifugation and size-exclusion chromatography, but it has been optimized for minimal vesicle loss while maintaining a high 
degree of purity. the protocol can be completed in less than 1 d and allows the recovery of ~150 mg of vesicle protein from a single 
mouse brain, thus allowing vesicle isolation from transgenic mice.
Experimental design
Our recently established procedure allows the isolation of func-
tionally active SVs from mammalian (mouse and rat) brain9. The 
protocol is essentially a hybrid of existing techniques, which have 
been optimized for yield and purity and which can be carried out in 
24 h or less. The protocol proceeds via the initial mild homogeniza-
tion of the brain to reduce fragmentation and vesiculation of large 
membranes, and it thus involves the isolation of a synaptosome-
enriched fraction from which SVs are released by osmotic rupture. 
Contrary to most other protocols, however, the vesicles released 
during the initial homogenization are also collected and combined 
with those released from the synaptosomes for further purification. 
Subsequent purification steps include a simplified rate-zonal sucrose 
density-step gradient, followed by size-exclusion chromatography 
on Sephacryl S-1000. With respect to purity, the final fraction com-
pares well with the classical procedure originally developed by Nagy 
et al.10 (and used with minor variations3,11), 
which currently constitutes the ‘gold stand-
ard’ in SV purification, despite being much 
more elaborate than the method described 
here. Importantly, though, the yield from 
our method is approximately sixfold higher. 
Thus, our protocol can be adopted for the 
isolation of SVs from a single mouse brain 
and, by extension, it opens up the possibility 
of using transgenic mouse lines in vesicle 
purification.
The protocol allows the quick and easy 
isolation of SVs from a single adult mouse 
brain9. However, it can easily be scaled up or 
down by a corresponding increase or reduc-
tion in the experimental volumes (noting 
that, in differential centrifugation, a change 
in volume will result in a change in the effec-
tive sedimentation properties). A flow diagram illustrating the pro-
cedure is given in Figure 2a. Illustrative photographs of the various 
experimental stages can be found in Supplementary Figure 1.
It should also be noted that the preparation of analytical amounts 
of SVs has been reported, using variations on the purification 
methods described here. These protocols include the use of floata-
tion gradients, following synaptosome lysis, to purify vesicles12 
and immunoaffinity purification, which takes advantage of the 
high binding affinity and specificity of an antibody for its antigen 
to allow SVs to be rapidly isolated13 (particularly after rate-zonal 
centrifugation of ‘semipure’ preparations on sucrose gradients2). 
For example, our protocol can be conveniently combined with 
immunoisolation, (i.e., by using our ‘combined supernatants’ as 
the starting material). Purity and functionality of vesicle prepara-
tions prepared using these variations can be checked using the same 
methods described in the ANTICIPATED RESULTS section.
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Figure 1 | Flow schematic illustrating the basic steps in SV purification using classical size-fractionation 
techniques.
MaterIals
REAGENTS
 crItIcal All reagents are available from Sigma-Aldrich unless otherwise 
stated and should be of analytical grade or higher.
Sucrose (cat. no. S7903)
HEPES (cat. no. H7523)
Tris-(hydroxymethyl)aminomethane (Tris; cat. no. T6791)
Protease inhibitors: PMSF (Roth, cat. no. 6367.3) and pepstatin A  
(Pepta Nova, cat. no. 4397)
Sephacryl S-1000 Superfine SF, 300–400-nm exclusion size (GE Healthcare, 
cat. no. 17-0476-01)
Marker antibodies (a full list of antibodies and suppliers can be found in 
Table 1)
ddH2O
Mice, 6–8 weeks postnatal, 25–30 g body weight, 0.5 g wet brain weight; 
or rats ! cautIon All experiments involving live rodents must conform to 
all relevant institutional and governmental ethics regulations.  
 crItIcal It should be noted that, in our hands, one whole brain from 
an adult rat is equivalent to two brains from adult mice on a wet weight:
wet weight basis. Although the procedure is described for mouse brains,  
rat brains can easily be used in this protocol with minor modifications,  
as indicated below.
EQUIPMENT
Sterile filtration unit with a 0.22-µm filter (Corning, cat. no. 431097) and 
vacuum pump
Motor-driven glass-Teflon homogenizers (1 ml and 17 ml with 0.1–0.15-mm  
clearance) (Omnilab, cat. nos. 5651690 and 5651694, respectively)
•
•
•
•
•
•
•
•
•
•
Cooled centrifuge; RC6 Plus (Sorvall) with SS34 rotor and 16-ml flanged 
polycarbonate (nonsealed) tubes with adapters (Beranek Laborgeraete,  
cat. nos. 252799 and 22006, respectively)
Ultracentrifuge (OptimaL-90K; Beckman Coulter) with Ti 50.2 and  
Ti 70.1 rotors and sealed polycarbonate tubes (cat. nos. 355618 and  
355603, respectively)
Equivalent centrifuges and tubes from other manufacturers can be used  
! cautIon Observe all safety precautions for the use of centrifuges.
Chromatography column (100 cm length × 1 cm inner diameter)  
(Bio-Rad, cat. no. 737-1091)
Peristaltic pump (Gilson, cat. no. F155001)
Fraction collector, UV detector unit and chart recorder (GE Healthcare,  
cat. nos. 18-1177-40, 11-0007-54 and 18-1132-32, respectively)
Typhoon FLA-7000 biomolecular imager (GE Healthcare, cat. no. 28-9558-09) 
equipped with appropriate filters or ImageQuant LAS 4000 image reader 
(GE Healthcare, cat. no. 28-9558-10)
REAGENT SETUP
Sucrose, 2 M Filter 2 M sucrose through a sterile 0.22-µm vacuum unit.  
The 2 M sucrose should be stored sterile at 4 °C (for at least 6 months),  
or divided into aliquots and frozen at  −20 °C until use (up to 12 months).
HEPES, 1 M Prepare two stock solutions with pH adjusted to 7.4 using 
NaOH or KOH. 1 M HEPES can be stored at 4 °C indefinitely.
Homogenization buffer Mix 320 mM sucrose and 4 mM HEPES (pH 7.4, 
adjusted with NaOH).  crItIcal This working sucrose solution should be 
made fresh on the day of use and kept at 4 °C until use.
•
•
•
•
•
•
•
Sucrose cushion Mix 700 mM sucrose and 10 mM HEPES (pH 7.4, adjusted 
with KOH).  crItIcal This working sucrose solution should be made fresh 
on the day of use and kept at 4 °C until use.
Chromatography buffer Mix 100 mM Tris-HCl (pH 7.6) and 100 mM KCl; 
filter the mixture through a 0.22-µm filter and degas it thoroughly before 
use.  crItIcal pH values of Tris buffers are temperature dependent, and 
thus pH should be adjusted at the working temperature (4 °C). Buffer can be 
stored at 4 °C indefinitely.
PMSF Prepare PMSF as a 200 mM stock solution in 100% ethanol.  
When stored at 4 °C, PMSF is stable for a maximum of 6 months.
Pepstatin A Prepare pepstatin A as a 1 mg ml − 1 stock solution in DMSO. 
When stored at 4 °C, pepstatin is stable for a maximum of 1 week.
Antibodies A full list of all primary antibodies suitable for detecting mouse 
proteins can be found in Table 1. Most of the listed antibodies should  
cross-react with the equivalent rat proteins. However, the reader is encour-
aged to check this for each individual antibody with the listed supplier.  
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Figure 2 | Schematic of an improved procedure 
for small-scale isolation of SVs from mammalian 
brain. (a) A flow diagram illustrating the 
purification protocol for SVs from mouse brain. 
Increased yield is achieved by combining 
SVs released into the supernatant during 
homogenization (S2) and those released 
from synaptosomes after osmotic lysis (LS1). 
Contamination of the SVs is reduced by the 
use of a sucrose cushion before size-exclusion 
chromatography on Sephacryl S-1000.  
(b) The distribution profiles of synaptophysin 
(SV marker) and Rpt4 (proteasome marker) 
after the centrifugation of the CS1 fraction 
on a sucrose cushion. In the CS1 fraction, SVs 
are enriched but still heavily contaminated. 
Direct fractionation of CS1 by size-exclusion 
chromatography removes some, but not all, of 
these contaminants (not shown). Prominent 
among the contaminants are proteasomes, 
which are effectively removed by use of the 
sucrose cushion. After centrifugation, fractions 
are taken and dot blot immunostaining is 
performed. As can be seen, SVs separate away 
from proteasomes under appropriate conditions. 
Further details can be found in supplementary 
Figure 2.
For accurate signal quantification from immunoblots, we recommend the 
use of fluorescently labeled secondary antibodies, which give a wider linear 
detection range compared with those using the horseradish peroxidase– 
enhanced chemiluminescence (HRP-ECL) system. We routinely use Cy3  
IgG goat anti-mouse and Cy5 IgG goat anti-rabbit (both from Dianova;  
cat. nos. 115-165-166 and 111-175-144); for ECL detection, we use HRP-
conjugated goat anti-mouse and HRP-conjugated goat anti-rabbit  
(both from Bio-Rad, cat. nos. 170-6516 and 170-6515). Secondary antibody 
stocks are prepared according to the suppliers’ instructions. HRP-conjugated 
antibodies are used at a dilution of 1:2,000 (vol:vol) and Cy3/Cy5 antibodies 
at a dilution of 1:2,000 (vol:vol). Signals are recorded (and quantified) either 
using a Typhoon FLA-7000 biomolecular imager equipped with appropri-
ate filters or using an ImageQuant LAS 4000 image reader. We imported the 
figures in this paper into Photoshop (Adobe), and we adjusted the contrast 
to best show the levels of proteins in the various subfractions relative to the 
starting homogenate.
EQUIPMENT SETUP
 crItIcal All equipment used during the procedure should be free of 
detergent. Glassware can be cleaned free of detergent by extensive washing 
in ethanol and ddH2O before use. When large numbers of preparations are 
required, we recommend purchasing separate equipment.
Sephacryl size-exclusion column Pack the Sephacryl size-exclusion  
column according to standard instructions, which are available at http://www.
gelifesciences.com/webapp/wcs/stores/servlet/catalog/en/GELifeSciences-DE/
products/AlternativeProductStructure_17395/17047601. A 100 cm × 1 cm 
column requires ~70 ml of packed resin. Before running the samples, thor-
oughly equilibrate the column with ten column-volumes of column buffer. 
To avoid the accumulation of debris, filter all buffers before use. During 
repetitive runs, we noticed that contaminants accumulate. In this case, we 
recommend replacing the entire column with new material. Alternatively, the 
column can be cleaned according to the manufacturer’s instructions; simple 
cleaning with a one-fifth column-volume of 0.1 M NaOH followed by a one-
fifth column-volume of 1 M acetic acid should suffice for all but the heaviest 
contamination. Before further use, thoroughly equilibrate the column in 
column buffer. The column should not run dry. If this occurs, a new column 
should be prepared. For long-term storage, equilibrate the column in column 
buffer containing 0.02% (wt/vol) sodium azide to prevent microbial growth.
taBle 1 | Antibodies used in this study.
protein supplier cat. no./type
apparent MW  
(sDs-paGe) (kDa) comments
Clathrin light chain SySy 113011 
Monoclonal
~30 Key component of the endocytic clathrin 
coat
Dynamin SySy 115002 
Polyclonal
~100 GTPase involved in vesicle scission 
during endocytosis
ERC1b/2 SySy 143003 
Polyclonal
~110 Neuronal active zone protein
Glial fibrillary acidic  
protein (GFAP)
AbD Serotec 46500280a 
Polyclonal
~50 Glial cell marker
Lactate dehydrogenase Santa Cruz Biotechnology SC-33781 
Monoclonal
~35 Soluble protein
mSec22 Custom Polyclonal27 Not applicable ~22 SNARE protein involved in endocplasmic 
reticulum (ER)-Golgi transport
Munc-18 SySy 116011 
Monoclonal
~66 Membrane protein involved in vesicle 
docking and fusion
mUse1 Custom Polyclonal27 Not applicable ~31 SNARE protein involved in ER–Golgi 
transport
Myelin basic protein Dako A0623 
Monoclonal
~20 Major protein component of the neuronal 
myelin sheath
Na + /K + -ATPase Abcam AB7671 
Monoclonal
~110 Na + /K +  transporter specific for the 
plasma membrane
NMDA-R1 SySy 114011 
Monoclonal
~110 Subunit of postsynaptic NMDA glutamate 
receptor
NSF SySy 123001 
Monoclonal
~68 Essential protein involved in SNARE 
complex disassembly
PSD-95 Neuromab 75-028 
Monoclonal
~110 Scaffolding protein at the postsynaptic 
density
Rab3a SySy 107111 
Monoclonal
~25 Small GTPase associated with SVs
Rab5 SySy 108011 
Monoclonal
~25 Small GTPase associated with SVs and 
recycling endosomes
Rab-GDI SySy 130011 
Monoclonal
~65 Regulator of Rab protein activity
Rpt 4 Abcam AB22639 
Monoclonal
~44 Proteasome component
Succinate  
dehydrogenase (SDHA)
Abcam AB14715 
Monoclonal
~70 Mitochondrial protein
SNAP-25 SySy 111111 
Monoclonal
~25 Plasma membrane SNARE protein 
involved in neuronal exocytosis
SNAP-47 SySy 111403 
Polyclonal
~50 SNARE protein first identified on SVs. 
Involved in LTP
Spliceosome 61K Custom Polyclonal28 Not applicable ~55 Protein component of the spliceosome
proceDure
! cautIon Before starting, experimenters should ensure that animal experiments are carried out in accordance with relevant 
local and institutional animal protection regulations.
part 1: release of sVs from whole brain ● tIMInG 45 min
1| Decapitate one mouse (6–8 weeks postnatal, 25–30 g body weight, 0.5 g wet brain weight) and remove the whole brain. 
Wash the brain thoroughly with homogenization buffer. 
 crItIcal step The use of brains from older mice results in lower purity of the final SV fraction. This is probably due to 
the higher degree of myelination in older mice, with myelin-derived membrane fragments being a probable source of  
contamination. 
 crItIcal step After collecting the brains, all steps are carried out on ice or at 4 °C.
2| Homogenize the brain in 9 ml of ice-cold homogenization buffer (freshly supplemented with protease inhibitors,  
0.001 volume), using a tight-fitting glass-Teflon homogenizer with ten strokes at 900 r.p.m. 
 crItIcal step As PMSF is unstable in aqueous solution, protease inhibitors should be added to the homogenization 
buffer only immediately before use. Stir the solution while adding protease inhibitors to avoid precipitation. Several vesicle 
proteins (e.g., synapsin I and synaptotagmin 1) are sensitive to proteolytic degradation by endogenous proteases.
? trouBlesHootInG
3| Centrifuge the homogenization mixture at 2,700 r.p.m. (1,000g) for 10 min at 4°C in an SS34 rotor. Collect the  
supernatant (S1). The resulting pellet (P1), which contains large cell fragments and nuclei, can be discarded. 
 crItIcal step When collecting supernatants, do not disturb the pellets (including any material at the periphery; 
supplementary Fig. 1). Inclusion of pellet material results in higher contamination of the final vesicle fraction.
4| Centrifuge the S1 at 11,000 r.p.m. (15,000g) for 15 min at 4°C in an SS34 rotor. Collect the supernatant (S2) and store 
it on ice. The S2 contains SVs, along with small cell fragments, such as microsomes, small myelin fragments and also  
soluble proteins. The resulting pellet (P2) contains synaptosomes. Wash the pellet by carefully resuspending it in 1 ml of 
homogenization buffer (avoid the brown bottom part of the pellet, which consists mainly of mitochondria).  
Resuspension is best performed using a 1-ml pipette with the end cut off at the tip.
5| To release SVs from the synaptosomes, transfer the fraction into a tight-fitting glass-Teflon homogenizer; add 9 vol 
(9 ml) of ice-cold ddH2O and perform three strokes at 2,000 r.p.m. Immediately add 50 µl of 1 M HEPES (NaOH) and protease 
inhibitors (0.001 volume). 
 crItIcal step Addition of protease inhibitors is critical at this stage because osmotic lysis of synaptosomes not only 
releases SVs but also neutral and lysosomal proteases into the solution.
taBle 1 | Antibodies used in this study (continued).
protein supplier cat. no./type
apparent MW  
(sDs-paGe) (kDa) comments
Synaptobrevin 2 SySy 104211 
Monoclonal
~18 Vesicular SNARE protein involved in 
neuronal exocytosis
Synaptophysin 1 SySy 101011 
Monoclonal
~38 Major SV membrane protein; involved in 
endocytosis
Synaptophysin 1 Custom polyclonal15 Not applicable ~38 Major SV membrane protein; involved in 
endocytosis
Synaptotagmin 1 SySy 105011 
Monoclonal
~60 Ca2 + -sensor on SVs
Syntaxin 1A SySy 110111 
Monoclonal
~36 Plasma membrane SNARE protein 
involved in neuronal exocytosis
VGLUT1 Custom polyclonal20 Not applicable ~60 Vesicular glutamate transporter
SySy, Synaptic Systems. Antibodies were used according to the supplier’s recommendations.
aThis antibody has been discontinued. Suitable alternative antibodies/markers may be GFAP from SySy (cat. no. 173 011), or Aldh1L1 from Neuromab (cat. nos. 73-140 or 75-140) ref. 29.
part 2: removal of contaminating proteins and membranes ● tIMInG 3 h 45 min
6| Centrifuge the lysate at 12,000 r.p.m. (17,000g) for 15 min at 4 °C in an SS34 rotor to remove all large membraneous 
particles (mostly mitochondria, junctional complexes and myelin). Collect the supernatant (LS1) and combine it with S2.
7| Centrifuge the LS1/S2 mixture at 20,000 r.p.m. (48,000g) for 25 min at 4 °C in an SS34 rotor.
8| Collect the supernatant (CS1) and transfer it into a tight-fitting glass-Teflon homogenizer. SVs have a tendency to  
aggregate during the isolation procedure; homogenize the supernatant using 3–5 strokes at 900 r.p.m. To ensure proper 
disruption of any remaining SV clusters, draw the supernatant through a 20-gauge hypodermic needle attached to a 10-ml 
syringe, and then change to a 27-gauge needle and expel. Avoid the formation of air bubbles and foaming during this step. 
 crItIcal step Proper disruption of clusters is essential to ensure uniform migration behavior in the subsequent centrifu-
gation step.
9| Overlay 5 ml of CS1 onto a 5-ml 0.7 M sucrose cushion. The number of tubes needed is dependent on the volume of CS1.
10| Centrifuge the sucrose cushion at 38,000 r.p.m. (133,000g) for 1 h at 4 °C in a 70.1 Ti rotor. 
 crItIcal step This rate-zonal centrifugation step separates SVs from protein particles, such as ribosomes and proteas-
omes, which otherwise co-sediment with SVs (see supplementary Fig. 2 for more details on the centrifugation procedure). 
In our experience, proteasomes constitute a major contaminant that contributes substantially to the total protein in the 
final SV fraction, thereby lowering the effective enrichment levels of bona fide vesicle proteins.
11| After centrifugation, collect 500-µl fractions, starting from the top of the gradient. Fractionate the whole gradient. 
Also recover the white pellet that forms at the bottom of the tube by gently ‘scraping’ the tube wall with a plastic spatula, 
followed by transferring the pellet to a 1-ml homogenizer. Use a pipette tip with the end removed to reduce problems with 
pellet adherence to the plastic. Add 200 µl of sucrose buffer and homogenize the mixture using three strokes at 900 r.p.m.
part 3: purity check by dot blotting ● tIMInG 9 h 15 min
12| Spot ~5 µl of each fraction (including the pellet) onto nitrocellulose paper and perform a dot blot assay (Fig. 2b; 
refs. 14,15). We include antibodies against an integral membrane protein on the SV (synaptophysin or synaptobrevin), 
as well as an antibody against a proteasome component (such as Rpt4).
13| SVs are usually found in fractions 12–20 (Fig. 2b). Combine these fractions with the pellet. Discard fractions 1–11. 
 crItIcal step Discarding the fractions with substantial overlap between Rpt4 and synaptophysin (fractions 10 and 11 in 
Fig. 2b) markedly improves the purity of the final vesicle fractions at the cost of lower yield. If high yield is more important 
than purity, these fractions may be included.
? trouBlesHootInG
14| Collect the SVs into a pellet by ultracentrifugation (for example, by centrifuging the fractions at 50,000 r.p.m. 
(300,000g) for 2 h in a 50.2 Ti rotor). Although a 70.1 Ti rotor can also be used at this stage, it uses low-capacity tubes. 
We prefer using the 50.2 Ti rotor, as the higher volume per tube results in the recovery of larger, easier-to-handle pellets.
part 4: size-exclusion chromatography as a final purification step ● tIMInG 1 h, followed by overnight running of the 
size-exclusion column
15| After centrifugation, discard the supernatant. Resuspend the pellet in 1 ml of column buffer (SV-P); transfer the buffer 
to a 1-ml tight-fitting glass-Teflon homogenizer and perform ten strokes at 900 r.p.m. Draw the supernatant through a  
20-gauge hypodermic needle attached to a 1-ml syringe; then change to a 27-gauge needle and expel. Again, avoid the 
formation of air bubbles and foaming during this step. 
 crItIcal step At this stage, it is estimated from electron micrographs that the vesicles are up to 20–30% contaminated 
by membranous fragments. Size-exclusion chromatography is omitted in many protocols but is essential in order to remove 
these remaining contaminating membranes and (if needed) remaining cytosolic proteins. 
 crItIcal step Two resins are available with a sufficiently large pore size that allows SVs to enter and, thus, to migrate 
behind the exclusion volume: controlled-pore glass beads10 (CPG-3000) and Sephacryl S-1000 (ref. 16). The former allows for 
robust columns that can be used for many years and can be operated at high flow rates because of the noncompressibility of 
the resin, resulting in substantially shortened separation times. Disadvantages include the low separation capacity (requiring 
sample:column ratios of 1:50 (vol/vol)), limited commercial availability and high costs. Here we describe the use of Seph-
acryl S-1000, which gives acceptable levels of performance. The 100 cm × 1 cm column used in this protocol can be used to 
purify SVs from one to four whole adult mouse brains, and the column size can be adjusted to accommodate smaller or larger 
samples from mice. It should be noted that, in our hands, one whole brain from an adult rat is equivalent to two brains from 
adult mice, on a wet weight:wet weight basis.
16| Load the SV-P onto an equilibrated Sephacryl S-1000 column and overlay it with column buffer. Connect the setup to 
a peristaltic pump and run it overnight with a flow rate of ~6 ml h − 1. Monitor the eluate by connecting a UV monitor to 
the bottom of the column (changes in signal at 280 nm will be due to a combination of aromatic amino acid absorbance by 
proteins and light scattering by larger particles). Collect the eluate coming through the UV monitor using a fraction collec-
tor. For best separation, individual fraction sizes of 0.7 ml are recommended. SVs should have eluted from the column after 
10 or 11 h. 
 crItIcal step Avoid the temptation to use higher flow rates to speed up elution from the column. Sephacryl columns do 
not tolerate increased pressure. This results in compression of the material, which adversely affects resolution. 
 crItIcal step Sephacryl columns have a tendency to adsorb protein and membrane particles, in particular during the first 
few separation runs on a new column. Several vesicle preparations are needed to ‘precondition’ the Sephacryl column. Optimal 
yields are usually only obtained after the first three or four preparations. Preconditioning should be performed with SV-P. Avoid 
the temptation to use crude fractions, such as LP1, or alternatives such as BSA, which will ultimately affect vesicle purity. 
 crItIcal step Unlike CPG columns, the resolving capacity of Sephacryl columns depends on buffers containing salts with 
concentrations in the physiological range. Note that synapsins, which are peripheral vesicle proteins, dissociate from the 
vesicle membrane under these conditions11. Elution buffers of lower ionic strength (as required to preserve synapsin binding) 
substantially reduce resolution and increase contamination of the final SV preparation.
17| A successful column run produces two absorption maxima on the chromatogram (Fig. 3). The first peak contains larger 
membrane fragments (in the range of 100–200 nm in size). SVs (50 nm diameter) are found in the second peak. To obtain 
pure SVs, combine the fractions indicated in Figure 3; start from four to five fractions before the second maxima and continue 
combining fractions until just before the small bump in the trace (which represents elution of SVs with fractured membranes 
from the column). If purity can be sacrificed for yield, more fractions can be collected on either side of this second peak.
part 5: collection and storage of purified sVs ● tIMInG 2 h 30 min
18| Pool the desired fractions and centrifuge at 50,000 r.p.m. for 2 h at 4 °C in a 50.2Ti rotor (300,000g; see Step 14). SVs 
should be visible as a clear, translucent pellet on the wall of the tube.
19| Discard the supernatant and resuspend the pellet (SV) in ~200 µl of the desired buffer. Transfer the buffer into a 1-ml 
tight-fitting glass-Teflon homogenizer and perform ten strokes at 900 r.p.m. Again, use a pipette tip with the end removed 
to reduce problems with pellet adherence to the plastic during transfer. Draw the supernatant through a 20-gauge hypoder-
mic needle attached to a 1-ml syringe; then change to a 27-gauge needle and expel, avoiding the formation of air bubbles 
and foaming.
? trouBlesHootInG
 pause poInt The purified SVs can be snap-frozen in liquid nitrogen and stored at  −80 °C.
Figure 3 | Effects of size-exclusion 
chromatography on SV purity. (a) Elution profile 
of the Sephacryl column (monitored at 280 nm). 
Roman numerals (i–iii) on the chromatogram 
refer to fractions analyzed by electron 
microscopy (negative stain) shown in b. P1 and 
SV brackets indicate fractions pooled following 
elution from the column. (b) Negative-stain 
electron microscopy of fractions eluting from the 
size-exclusion column. The large, heterogeneous 
membrane structures present in the loading 
fraction (v; SV-P-containing membranes with 
diameters of 100 nm or more) are concentrated 
in the first peak (P1) after chromatography (i). 
Homogenous small SVs with diameters ranging 
from 40 to 50 nm should be concentrated in the 
second peak (SV; iii). Fractions between these two peaks typically contain low amounts of membranes in both size ranges (ii). More than 90% of these small 
vesicles are immunopositive for the specific vesicle marker synaptophysin (iv; the inset shows immunogold-labeled vesicles at a higher magnification).  
Scale bars in b: 500 nm (i–iii); 100 nm (iv, inset, v).
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Troubleshooting advice can be found in table 2.
taBle 2 | Troubleshooting table.
step problem possible reason solution
2 PMSF solubility Use of ice-cold buffers PMSF is difficult to dissolve in ice-cold buffer. Add slowly 
to solution, while stirring quickly. Expel the PMSF from the 
pipette slowly and continuously. Do not remove the pipette 
from the solution until the PMSF is fully added
13 Major contamination by 
proteasomes (as judged by 
Rpt4 immunoreactivity)
Incorrect migration of SVs in  
gradient during centrifugation
SVs have a tendency to aggregate during the isolation  
procedure. Increase homogenization of CS1 and pull/expel 
through 20/27-gauge needles multiple times 
Convex mixing of CS1 and sucrose cushion. Take care when 
layering CS1 onto the cushion 
Incorrect centrifugation conditions. Check rotors, speeds and 
so on. Systematically vary centrifugation conditions until dot 
blotting shows clear separation
Poor fractionation technique Gradients are fractionated from top to bottom. To ensure a 
clean fractionation, the pipette tip should be just in contact 
with the top of the gradient, not immersed under the surface. 
Fractions should be removed slowly
19 Poor vesicle yield Adsorption of membranes and 
proteins onto Sephacryl
Run several vesicle preparations to ‘pre-condition’ Sephacryl 
column
SV protein degradation 
(particularly synaptotag-
min 1)
Protease activity Chill all buffers and centrifuge rotors before use. Keep sam-
ples on ice wherever possible, or at 4 °C 
Check protease inhibitor activity. Prepare new stocks and add 
to the buffers immediately before use. Check whether PMSF 
has dissolved fully 
Consider changing to Roche Complete tablets (EDTA-free), 
which are broad-spectrum protease inhibitor tablets and 
which retain stability in aqueous solution (Roche,  
cat. no. 1 873 580)
Contamination (large  
membrane fragments)
Too vigorous homogenization of 
whole brain
Incorrect homogenizer clearance 
Try varying the initial homogenization conditions
Contamination (membrane 
fragments and proteins)
Poor resolution of size-exclusion 
column
Check individual fractions eluting from the size-exclusion 
column by negative-stain electron microscopy. Only pool 
fractions containing pure vesicles (~40–50 nm diameter) 
Repack column. Generally longer columns give better  
separation 
Avoid Sephacryl compression due to excessive column  
pressure. Check the flow rate 
Avoid overloading the column with material 
Collect smaller volumes (shorten the collection time) for 
individual fractions
Contamination (proteins; 
myelin)
Completion of myelination  
relative to synapse formation 
is late
Use younger animals
Contamination (proteins; 
miscellaneous markers)
Poor fractionation technique Avoid cross-contamination of pellets and supernatants during 
the procedure
Incorrect pooling of fractions 
following size-exclusion  
chromatography
Dot blot individual fractions eluting from the size-exclusion 
column to identify fractions enriched in contaminating  
proteins and those enriched in SV markers
● tIMInG
Steps 1–5, release of SVs from whole brain: 45 min
Steps 6–11, removal of contaminating proteins and membranes: 3 h 45 min
Steps 12–14, purity check by dot blotting: 9 h 15 min
Steps 15–17, size-exclusion chromatography as a final purification step: 1 h, followed by overnight running of the 
size-exclusion column
Steps 18 and 19, collection and storage of purified SVs: 2 h 30 min
antIcIpateD results
The yield of SVs obtained using this preparation is ~300 µg of total protein per gram brain wet weight, which is approxi-
mately sixfold higher than that of the classical procedure using rat brain15 and more than two times higher than an alterna-
tive preparation claiming enhanced yield with comparable purity8. SVs that are purified and frozen remain structurally intact 
and functional (without loss of activity) for many months—as judged by the following criteria.
For studies of SV structure and function, it is essential to show that the vesicle fraction is free both from contamination 
by other membranes and particles produced as a by-product of the fractionation procedure and from associated cytoplasmic 
components. Traditionally, the methods used for assessing purity were largely confined to electron microscopic analysis of 
size and shape and to enzymatic assays to test for contaminating proteins originating from the mitochondria. Although 
electron microscopy remains a powerful tool, the identification of SV-specific proteins, such as synapsins, synaptotagmin and 
synaptophysin, means that biochemical homogeneity is now more easily assessed with immunological techniques such as 
immunoblotting—which allows SVs to be differentiated from other cellular transport vesicles or from vesiculated membrane 
fragments of similar size, which may have been generated during initial tissue homogenization.
In negative-stain electron micrographs, the final vesicle fraction should consist mainly of uniformly sized vesicles,  
with diameters ranging from 40 to 50 nm. More than 90% of these vesicles should be immunoreactive for the integral  
membrane protein synaptophysin (Fig. 3b). Furthermore, enrichment and yield, as well as the degree of contamination by 
other organelles and particles, can be monitored by immunoblotting fractions obtained during the purification for known 
taBle 3 | Quantification of SV enrichment during the isolation procedure.
Fraction
protein concentration 
(mg ml − 1)a Volume (ml)
total 
protein (mg)
total protein 
% of H
synaptophysin 
% of H enrichment factor
H 4.8 ± 0.5 18.9 ± 0.8 90.1 ± 12.3 100.0 ± 0.0 100.0 ± 0.0 1.0 ± 0.0
P1 8.7 ± 1.4 2.6 ± 0.4 22.4 ± 5.3 25.0 ± 4.4 19.0 ± 4.1 0.8 ± 0.1
S1 3.7 ± 0.6 17.0 ± 1.0 63.3 ± 10.5 70.0 ± 2.2 63.0 ± 6.7 0.9 ± 0.1
P2 7.8 ± 1.3 2.9 ± 0.2 22.4 ± 2.4 25.0 ± 2.9 33.0 ± 6.6 1.3 ± 0.2
S2 2.1 ± 0.5 15.3 ± 1.5 32.0 ± 7.3 35.0 ± 3.0 28.0 ± 1.0 0.8 ± 0.1
LP1 7.5 ± 1.1 1.7 ± 0.6 12.5 ± 7.0 14.0 ± 5.3 15.0 ± 7.8 1.1 ± 0.2
LS1 0.2 ± 0.1 15.5 ± 3.9 3.4 ± 1.2 4.0 ± 1.7 4.5 ± 1.7 1.1 ± 0.3
CP1 10.8 ± 1.9 1.1 ± 0.1 12.2 ± 2.8 14.0 ± 4.4 13.0 ± 0.2 0.9 ± 0.3
CS1 0.8 ± 0.1 30.2 ± 2.9 23.1 ± 2.7 26.0 ± 6.5 17.0 ± 2.1 0.7 ± 0.2
CS2P 3.4 ± 0.5 0.1 ± 0.1 0.5 ± 0.3 0.5 ± 0.4 0.5 ± 0.4 1.0 ± 0.0
SV-P 2.7 ± 0.3 0.7 ± 0.1 2.0 ± 0.2 2.2 ± 0.2 9.0 ± 1.9 4.1 ± 0.2
PI 0.8 ± 0.5 0.1 ± 0.1 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 0.7 ± 0.1
PII 0.7 ± 0.4 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.2 ± 0.1 1.7 ± 0.5
SV 1.2 ± 0.1 0.2 ± 0.0 0.2 ± 0.0 0.3 ± 0.1 5.4 ± 1.0 20.0 ± 1.0
The table shows the total protein recovery and relative enrichment of synaptophysin in the various subfractions taken during the isolation procedure, as assessed by quantitative immunoblotting.  
For synaptophysin, the enrichment in the final vesicle fraction should be ~20-fold over the starting homogenate. A similar level of enrichment should also be seen for other integral membrane proteins,  
such as synaptotagmin and synaptobrevin. Note the large amount of synaptophysin present in the S2 fraction, which would be lost in other protocols (Fig. 2). aProtein concentrations and volumes are given  
as indicators for a typical experiment. Protein concentration was measured using a modified Lowry procedure, with BSA as a protein standard. Figures represent the mean ± s.d. from three independent  
experiments. Each experiment was performed using two mouse brains as the initial starting material. Figures are rounded to one decimal place.
a b
H
(kDa)
P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
H P1 S1 P2 S2 LP1 LS1 CP1 CS1 CS2P SV-P PI PII SV
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Figure 4 | Separation by SDS-PAGE of subfractions taken during the isolation 
of SVs. (a) Coomassie Blue staining. A volume of 5 µg of total protein 
from each fraction was subjected to SDS-PAGE, followed by Coomassie 
staining. SVs (from mouse) have a characteristic protein profile. In a clean 
preparation, major protein bands at 18 kDa and 38 kDa should be clearly 
visible, which correspond to the major membrane proteins synaptobrevin and 
synaptophysin (arrowheads). (b) Immunoblots of the various subfractions. 
A volume of 5 µg of total protein from each fraction was subjected to 
SDS-PAGE, followed by immunoblotting for various marker proteins. 
Known integral membrane proteins on SVs should enrich from homogenate 
to the final vesicle fraction. By contrast, proteins that are regarded as 
contaminants should be lost during the final purification steps. The dynamin 
antibody used does not discriminate between dynamin isoforms 1, 2 and 3, 
all of which are expressed in the brain. Note that to allow the most efficient 
use of membranes, they were cut into individual strips in the appropriate 
size range, as the specificity of all the antibodies used has been tested in 
previous publications (table 1). 
to SVs in size. Rate-zonal gradient centrifugation turned out to be crucial to their removal, as these particles migrate more 
slowly than SVs, although their buoyant density is higher. Note that it is not possible to completely free the final SV fraction 
from transport vesicles that share similar physical properties, such as those involved in the traffic between the endoplasmic 
reticulum and the Golgi apparatus (mSec22 and mUse1).
Under optimal conditions, the purity of our preparation compares well with that of the classical protocol developed by 
Whittaker and colleagues6, in which an extraordinary homogeneity can be obtained (ideally 99% purity; Huttner et al.11). 
With our preparation, the degree of contamination by other membranes is usually lower than 10%, as judged both by mor-
phology and immunolabeling. Furthermore, the enrichment of synaptophysin per mg of protein (20-fold) compares well with 
that of the classical protocol (23-fold; table 3 and Jahn et al.15).
Purified SVs should also retain the ability to perform their primary in vivo functions—the ability to transport and store 
neurotransmitters and to fuse with the plasma membrane. Vesicular neurotransmitter uptake is mediated by specific  
transporters that depend on the proton electrochemical potential that exists across the vesicle membrane and which is  
generated by a vacuolar ATPase. Thus, vesicles purified using our procedure should show ATP-dependent glutamate uptake 
that is sensitive to the uncoupler carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (Fig. 5a). Failure to transport  
glutamate may well represent dissociation of the ATPase during purification (which is a problem associated with all  
marker proteins. In general, markers for SVs, such as  
synaptophysin, synaptobrevin, vesicular neurotransmitter 
transporters and synaptotagmin, should all enrich in  
parallel, with the highest (typically 20-fold) enrichment 
being in the final SV fraction (table 3). In contrast, markers 
for myelin and glia (MBP and GFAP), plasma membranes  
(for example, Na + /K + -ATPase and NMDA-R1) and mitochon-
dria (SDHA) should be depleted (or at least not enriched) in 
the final fractions (Fig. 4 and supplementary Fig. 3).  
The removal of protein super-complexes including protea-
somes and spliceosomes (and perhaps ribosomes) proved 
to be the most difficult task, as these particles are similar 
preparations)17, or membrane damage that prevents the maintenance of a stable membrane potential. In vivo, fusion of SVs 
is mediated by SNARE (soluble NSF attachment protein receptor) proteins on the plasma membrane. Purified SVs should fuse 
with artificial membranes (liposomes) containing syntaxin 1 and SNAP-25 (Fig. 5b)18. Fusion should be SNARE dependent. 
No fusion should be seen between SVs and empty liposomes, or when the vesicular SNARE protein synaptobrevin is cleaved 
with the light chain of tetanus toxin. Fusion should also be effectively inhibited when liposomes and SVs are preincubated 
for 60 min at room temperature (20 °C) with the cytoplasmic fragments of either synaptobrevin or syntaxin/SNAP-25,  
respectively, as expected for competitive SNARE inhibition.
Detailed protocols for these assays—protein determination (Lowry method) and SDS-PAGE, Coomassie Brilliant Blue stain-
ing, immunoblotting, electron microscopy, glutamate uptake and vesicle fusion—have all been published previously3,8,18–21.
anticipated uses Purified SVs were instrumental in identifying key proteins involved in exocytosis, such as synaptotagmin 
and synaptobrevin. Furthermore, purified SVs were the starting point for identifying novel families of membrane proteins that 
are probably involved in trafficking, including synaptophysins, synaptogyrins and SV2. More recently, SVs have served as a 
benchmark for comprehensive organelle proteomics2,3. Furthermore, purified SVs were used to develop the first quantitative 
molecular model of a trafficking organelle3. With the increase in sensitivity in many analytical tools, such as proteomics and 
fluorescence-based single-particle analysis, the ability to isolate SVs at high purity from small samples such as single mouse 
brains opens a new window for comparative biochemistry, involving both structural and functional approaches. In particu-
lar, the vesicle preparation described here will be very useful in the characterization of the increasing variety of transgenic 
mouse lines that contain targeted alterations of vesicular and other synaptic components. Furthermore, vesicles isolated from 
mice carrying GFP-tagged SV proteins will provide novel tools for refined in vitro analysis, which so far has not been possible. 
Notably, our preliminary experiments also suggest that the use of transgenic animals will not be limited to those that survive 
to adulthood; experiments aimed at ‘downscaling’ the protocol still further indicate that it will be possible to eventually 
purify SVs from embryonic brains for analysis.
Many in vitro assays are available for the study of various aspects of SV function. The substantially increased yield achieved 
by our protocol will both increase experimental throughput and reduce the number of animals that need to be killed for a 
given experiment. In addition to neurotransmitter uptake and in vitro reconstitution of SNARE-mediated membrane fusion, 
isolated SVs can be used to study, for instance, the function of the vacuolar ATPase8,22, to monitor binding and unbinding of 
Rab-GTPases23, to measure dissociation of other peripheral proteins such as synapsins11, to map the topology of membrane 
proteins24,25 and to study the function of the calcium sensor synaptotagmin26.
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Figure 5 | Testing SV function. (a) [3H]l-glutamate uptake by SVs isolated 
from mouse brain. SVs containing the vesicular glutamate transporter will 
accumulate glutamate under appropriate assay conditions. Glutamate uptake  
requires ATP-dependent vesicular acidification (produced by the vesicular 
proton pump). Addition of the uncoupler carbonyl cyanide p-(trifluoromethoxy) 
phenylhydrazone (FCCP) prevents glutamate uptake by dissipation of the 
proton gradient. Experiments were repeated five times for each condition, 
represented by the average uptake ± s.d. (b) A fluorescent resonance energy 
transfer (FRET)-based lipid-mixing assay reports SNARE-mediated fusion of 
purified mouse SVs with liposomes. FRET occurs between the dyes NBD and 
Rhodamine, which are individually coupled to lipids used in the liposome 
preparation. FRET decreases (resulting in a measurable increase in NBD 
fluorescence) when vesicles fuse with liposomes containing the SNARE 
proteins syntaxin 1 and SNAP-25 (Syx/SN25 liposomes). This occurs as the 
larger (unlabeled) surface area of the fusion product allows greater spatial separation of the two dyes, resulting from lipid diffusion. In this figure, fusion 
is normalized to the total NBD fluorescence measured after liposomes are completely solubilized by Triton X-100, resulting in maximal spatial separation of 
NBD and Rhodamine. Fusion should be SNARE dependent. No fusion should be seen between SVs and empty liposomes, or when the vesicular SNARE protein 
synaptobrevin is cleaved with the light chain of tetanus toxin (TeNT). Fusion should also be effectively inhibited when liposomes and SVs are preincubated 
for 60 min at room temperature with the cytoplasmic fragments of either synaptobrevin or syntaxin/SNAP-25, respectively, as expected for competitive SNARE 
inhibition. Traces are representative of a typical experiment.
Note: Supplementary information is available in the online version of the paper.
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